内美制药公司报告口服阿尔茨海默氏病治疗 INM-901显示 治疗性大脑水平 InMed Pharmaceuticals reports oral Alzheimer's treatment INM-901 demonstrates therapeutic brain levels.

内美制药公司宣布,其口服配方INM-901成功地展示了阿尔茨海默氏病治疗的大脑治疗水平。 InMed Pharmaceuticals Inc. announced that its oral formulation INM-901 has successfully demonstrated therapeutic levels in the brain for Alzheimer's disease treatment. 小分子药物候选者经过成功的临床前研究,有可能降低治疗费用,并应对与现有大型分子疗法有关的挑战。 The small molecule drug candidate, following successful preclinical research, could potentially lower treatment costs and address challenges associated with existing large molecule therapies. INMED正在继续进一步研究,包括化学、制造和控制,以支持IND提交材料。 InMed is continuing with further research, including chemistry, manufacturing, and controls, to support an IND submission.